{"id":"fixed-combination-bimatoprost-and-timolol","safety":{"commonSideEffects":[{"rate":"null","effect":"Eyelash growth"},{"rate":"null","effect":"Itching"},{"rate":"null","effect":"Redness of the eye"},{"rate":"null","effect":"Dry mouth"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1200963","moleculeType":"Small molecule","molecularWeight":"415.57"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bimatoprost works by binding to prostaglandin receptors in the eye, leading to increased outflow of aqueous humor and decreased intraocular pressure. Timolol, on the other hand, blocks beta-adrenergic receptors, reducing the production of aqueous humor and subsequently lowering intraocular pressure.","oneSentence":"Bimatoprost is a prostaglandin analog that lowers intraocular pressure by increasing uveoscleral outflow, while Timolol is a beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:54:24.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT06761313","phase":"PHASE4","title":"Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2021-03-01","conditions":"Glaucoma, Quality of Life (QOL)","enrollment":40},{"nctId":"NCT04828057","phase":"","title":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2021-09-01","conditions":"Ocular Surface Disease, Primary Open Angle Glaucoma","enrollment":50},{"nctId":"NCT01206361","phase":"","title":"Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-02","conditions":"Glaucoma, Ocular Hypertension","enrollment":2015},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT01170884","phase":"PHASE4","title":"Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":121},{"nctId":"NCT01999348","phase":"","title":"A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-11-25","conditions":"Glaucoma, Primary Open Angle, Ocular Hypertension","enrollment":1553},{"nctId":"NCT01243567","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06-01","conditions":"Glaucoma, Open-Angle","enrollment":81},{"nctId":"NCT02742649","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2016-04-30","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":55},{"nctId":"NCT01217606","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":185},{"nctId":"NCT01230736","phase":"PHASE4","title":"Safety and Efficacy of Changing to DuoTrav From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-10","conditions":"Glaucoma","enrollment":105},{"nctId":"NCT01241240","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-03","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":192},{"nctId":"NCT02154217","phase":"PHASE3","title":"Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures","status":"COMPLETED","sponsor":"University of Milan","startDate":"","conditions":"Glaucoma","enrollment":200},{"nctId":"NCT01263444","phase":"PHASE4","title":"Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT01448837","phase":"PHASE4","title":"24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2010-04","conditions":"Glaucoma","enrollment":37},{"nctId":"NCT01327599","phase":"PHASE4","title":"Efficacy of Changing to DUOTRAV® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-08","conditions":"Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma","enrollment":60},{"nctId":"NCT01978015","phase":"PHASE4","title":"Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2011-10","conditions":"Uveitis, Anterior, Cystoid Macular Edema","enrollment":69},{"nctId":"NCT01216943","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":126},{"nctId":"NCT01177098","phase":"PHASE3","title":"Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":561},{"nctId":"NCT01628601","phase":"","title":"GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-05","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":392},{"nctId":"NCT01542710","phase":"NA","title":"Bimatoprost/Timolol Versus Travoprost/Timolol","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2011-01","conditions":"Glaucoma","enrollment":80},{"nctId":"NCT01168414","phase":"PHASE3","title":"A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Ministry of Health, Malaysia","startDate":"2010-08","conditions":"Ocular Hypertension, Primary Open Angle Glaucoma","enrollment":42},{"nctId":"NCT00332540","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2001-08","conditions":"Ocular Hypertension","enrollment":520},{"nctId":"NCT00332072","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2001-08","conditions":"Ocular Hypertension","enrollment":541},{"nctId":"NCT00332059","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2003-05","conditions":"Ocular Hypertension","enrollment":445},{"nctId":"NCT00941096","phase":"PHASE4","title":"Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed Combination","status":"COMPLETED","sponsor":"Larissa University Hospital","startDate":"2009-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GANFORT® UD"],"phase":"phase_2","status":"active","brandName":"Fixed Combination Bimatoprost and Timolol","genericName":"Fixed Combination Bimatoprost and Timolol","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bimatoprost is a prostaglandin analog that lowers intraocular pressure by increasing uveoscleral outflow, while Timolol is a beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}